Not logged in...
About USC Norris
Research
Patient Care
CISO
Search Trials
FAQ - Trials
Contact Us - Trials
Membership
Education
Shared Resources
Support USC Norris
Outreach
Login/Logout
Contact USC Norris
Support Us
Donate
Menu
USC Norris
»
Clinical Trials
Trial 0C-13-7
A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment
Type:
Treatment
Phase:
Phase I
Status:
Not Open (Closed)
Treatments:
Chemotherapy: Systemic
Randomized:
No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:
Heinz Josef Lenz, M.D.
Other Trial Staff:
Anayansi Miloud, D.M., Xiomara Menendez, R.N., Khatchik Karakozian, D.M., Molly Oswald, R.N.
Staff may
log in
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
clinical.trials@med.usc.edu
.
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.